Related Experiment Videos
Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS
1Service de Maladies Infectieuses et Tropicales, CHU Bichat-Claude Bernard, Paris, France.
Abstract:
A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acute Toxoplasma encephalitis in patients with AIDS. Of the 14 patients given 75 mg pyrimethamine and 500 mg azithromycin daily for four weeks, eight were evaluable for clinical response. Five responded favorably, one had an intermediate response and two an unfavorable response. Of the nine patients evaluable for radiological response, six responded favorably, and three had an intermediate response. Eleven adverse events occurred in nine patients: rash (n = 5), abnormal liver function (n = 2), vomiting (n = 3) and hypoacousia (n = 1). This pilot study suggests that the combination of pyrimethamine and azithromycin may be further investigated and that the optimal dosage of azithromycin has yet to be determined.
Insights
This study explored azithromycin and pyrimethamine for Toxoplasma encephalitis in AIDS patients. The combination showed promise, but further research is needed to determine optimal azithromycin dosage.
Area of Science:
- Infectious Diseases
- Neurology
- Pharmacology
Background:
- Toxoplasma encephalitis is a serious opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Standard treatments may have limitations, necessitating exploration of alternative therapeutic regimens.
Purpose of the Study:
- To evaluate the efficacy and safety of azithromycin in combination with pyrimethamine for treating acute Toxoplasma encephalitis in AIDS patients.
- To assess clinical and radiological responses to this combination therapy.
Main Methods:
- A prospective pilot study involving 14 patients with AIDS and acute Toxoplasma encephalitis.
- Patients received a daily dose of 75 mg pyrimethamine and 500 mg azithromycin for four weeks.
- Clinical and radiological responses were assessed, along with adverse events.
Main Results:
- Among eight evaluable patients for clinical response, five showed favorable outcomes, one intermediate, and two unfavorable.
- Six of nine patients evaluable for radiological response had favorable outcomes, and three had intermediate responses.
- Common adverse events included rash, abnormal liver function, vomiting, and hypoacousia.
Conclusions:
- The combination of pyrimethamine and azithromycin shows potential for treating Toxoplasma encephalitis in AIDS patients.
- Further investigation is warranted to confirm efficacy and establish optimal azithromycin dosage.
- The safety profile requires careful monitoring due to observed adverse events.